FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) [Yahoo! Finance]
Alector, Inc. (ALEC)
Last alector, inc. earnings: 3/24 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to latozinemab, an investigational human monoclonal antibody designed to block sortilin to elevate progranulin (PGRN) levels for the potential treatment of frontotemporal dementia with a progranulin gene mutation (FTD- GRN “In partnership with GSK, we are encouraged and excited by this FDA Breakthrough Designation. FTD- GRN is a rare and rapidly progressing neurodegenerative disease and one of the most common causes of early onset dementia," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. “With this designation, we look forward to continued productive conversations with the FDA, recognizing the unmet need for people living with FTD- GRN , a serious condition for which there are no FDA-approved treatment options available. Latozinemab, the
Show less
Read more
Impact Snapshot
Event Time:
ALEC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALEC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALEC alerts
High impacting Alector, Inc. news events
Weekly update
A roundup of the hottest topics
ALEC
News
- Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know [Yahoo! Finance]Yahoo! Finance
- The past five years for Alector (NASDAQ:ALEC) investors has not been profitable [Yahoo! Finance]Yahoo! Finance
- Alector, Inc. (NASDAQ: ALEC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $41.00 price target on the stock.MarketBeat
- Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Alector to Participate in Upcoming Healthcare ConferencesGlobeNewswire
ALEC
Earnings
- 2/27/24 - Beat
ALEC
Analyst Actions
- 2/28/24 - HC Wainwright
ALEC
Sec Filings
- 5/2/24 - Form 4
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form ARS
- ALEC's page on the SEC website